Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery (NCT07383909) | Clinical Trial Compass
RecruitingNot Applicable
Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery
China1,296 participantsStarted 2026-01-05
Plain-language summary
The goal of this clinical trial is to learn if a technique called remote ischemic preconditioning (RIPC) helps protect organs during emergency surgery for acute type A aortic dissection (ATAAD). The main questions it aims to answer are:
Does RIPC reduce the risk of major complications after surgery, such as heart, brain, or kidney problems?
Is RIPC safe to use during emergency ATAAD surgery?
Researchers will compare the RIPC group to a control group (who will receive a placebo) to see if RIPC can reduce complications after surgery.
Participants will:
Receive either RIPC or a sham intervention during their surgery.
Be monitored for up to 30 days after surgery for complications.
Have follow-up visits at 3 months, 1 year, and then yearly for up to 5 years to track their recovery.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥18 years, with no restriction on sex;
✓. Diagnosis of acute Type A aortic dissection requiring emergency surgery (symptom onset \<14 days);
✓. Ability to understand the study objectives, voluntary provision of written informed consent by the patient or a legally authorized representative, and willingness to comply with follow-up.
Exclusion criteria
✕. Traumatic or iatrogenic aortic dissection;
✕. Previous open cardiac or thoracic aortic surgery;
✕. Severe preoperative dysfunction of vital organs, such as persistent deep coma, abdominal compartment syndrome, or circulatory failure;
✕. Severe comorbidities, including myocardial infarction within the past 7 days, stroke within the past 2 months; end-stage renal disease (eGFR \<30 ml/min/1.73 m²); end-stage liver disease (total bilirubin \>342 μmol/L or INR \>2.0);
✕. Evidence of ischemia in the limb planned for intervention, such as decreased skin temperature, pain, pallor, with or without sensory disturbance, paralysis, or diminished/absent pulses; or severe deformity or prior arteriovenous surgery at the intervention site;
What they're measuring
1
In-hospital major adverse outcomes
Timeframe: surgery to discharge or 30 days post-op
✕. Peripheral arterial disease involving the limbs, Raynaud phenomenon, active phlebitis, or a history of deep vein thrombosis of the lower extremities;
✕. Current use of sulfonylurea oral hypoglycemic agents or nicorandil;
✕. Life expectancy \<1 year (e.g., advanced malignancy);